Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOMCT02 Huntington’s disease trial recruits 50% of patient target
On November 2, 2018, the SOMCT02 clinical trial successfully recruited its 15th patient, marking 50% […]
SOM Biotech invited to “Preferències” radio show
Each month, “Preferències” director and host Josep Maria Carrasco presents companies of special interest located […]
SOM Biotech at BIO Europe 2018
Europe’s largest annual life science partnering conference will be held on November 5-7, 2018 in Copenhagen. BIO […]
SOM Biotech joins Euronext TechShare Programme
Euronext, the first and largest pan-European stock exchange in the Eurozone, launched its fourth session of TechShare, the […]
Workshop on Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy
The 3rd Workshop on the Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy was held […]
World Duchenne Awareness Day 2018
September 7 is World Duchenne Awareness Day. In celebration of this awareness-raising event, SOM Biotech […]
SOM Biotech at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology 2018
BIT’s 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on […]
First patient recruited to SOMCT02 Huntington’s disease trial
The SOMCT02 trial has recruited its first patient on 8th August 2018 at the Hospital […]
SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington’s Disease Patients
BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 — SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs […]
SOM Biotech presents to the BIO.NRW Investors Circle
This year, SOM Biotech was invited to present to the Investors Circle of the Business Angel […]